An information-theoretic analysis of genetics, gender and age in cancer patients

PLoS ONE

Volumn 3, Issue 4, 2008, Pages

  Atwal, Gurinder Singh ^a   Rabadán, Raúl ^a   Lozano, Guillermina ^c   Strong, Louise C ^c   Ruijs, Mariëlle W G ^d,e   Schmidt, Marjanka K ^d   van't Veer, Laura J ^d   Nevanlinna, Heli ^f   Tommiska, Johanna ^f   Aittomäki, Kristiina ^f   Bougeard, Gaelle ^g   Frebourg, Thierry ^g   Levine, Arnold J ^a,b   Bond, Gareth L ^a,h  

^a INSTITUTE FOR ADVANCED STUDY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g ROUEN UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOINFORMATICS; CANCER GENETICS; CANCER GROWTH; CANCER PATIENT; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CARCINOGENESIS; CHILD; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PHENOTYPE; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; AGE; GENETIC PREDISPOSITION; GENETICS; MEDICAL INFORMATICS; MUTATION; NEOPLASM; PATHOLOGY; SEXUAL DEVELOPMENT; SIGNAL TRANSDUCTION; THEORETICAL MODEL; TUMOR SUPPRESSOR GENE;

AGE FACTORS; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MEDICAL INFORMATICS; MODELS, THEORETICAL; MUTATION; NEOPLASMS; PHENOTYPE; SEX CHARACTERISTICS; SEX FACTORS; SIGNAL TRANSDUCTION; VARIATION (GENETICS);

EID: 44849121764     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001951     Document Type: Article

References (37)

1. Lain S, Lane D (2003) Improving cancer therapy by non-genotoxic activation of p53. Eur J Cancer 39: 1053-1060.
2. Garber JE, Friend SH, Strong LC, Patenaude AF, Juengst ET, et al. (1992) Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Journal of the National Cancer Institute 84: 1156-1160.
3. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, et al. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872.
4. Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238.
5. Olive KP, Tuveson DA, Rube ZC, Yin B, Willis NA, et al. (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860.
6. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602.
7. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, et al. (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43: 531-533.
8. Ruijs MW, Schmidt MK, Nevarliinna. H, Tommiska J, Aittomaki K, et al. (2007) The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 15: 110-114.
9. Tabori U, Nanda S, Druker H, Lees J, Malkin D (2007) Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res 67: 1415-1418.
10. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, et al. (2005) A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 280: 26776-26787.
11. Hirata. H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, et al. (2007) MDM2 SNP309 Polymorphism as Risk Factor for Susceptibility and Poor Prognosis in Renal Cell Carcinoma. Clin Cancer Res 13: 4123-4129.
12. Hong Y, Miao X, Zhang X, Ding F, Luo A, et al. (2005) The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65: 9582-9587.
13. Bond GL, Hu W, Levine AJ (2005) MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5: 3-8.
14. Bond GL, Hu W, Levine A (2005) A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 65: 5481-5484.
15. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, et al. (2005) The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42: 694-698.
16. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, et al. (2006) MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Homone-Dependent Manner. Cancer Res 66: 5104-5110.
17. Bond GL, Levine AJ (2007) A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 26: 1317-1323.
18. Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, et al. (2006) MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet 43: 950-952.
19. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A (2006) Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 119: 718-721.
20. Hu W, Feng Z, Ma L, Wagner J, Rice JJ, et al. (2007) A Single Nucleotide Polymorphism in the MDM2 Gene Disrupts the Oscillation of p53 and MDM2 Levels in Cells. Cancer Res 67: 2757-2765.
21. Chompret A, Brugieres L, Ronsin M, Gardes M, Dessarps-Freichey F, et al. (2000) P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 82: 1932-1937.
22. Hwang SJ, Lozano G, Amos CI, Strong LC (2003) Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet 72: 975-983.
23. Sherriff A, Ott J (2001) Applications of neural networks for gene finding. Adv Genet 42: 287-297.
24. Province MA, Shannon WD, Rao DC (2001) Classification methods for confronting heterogeneity. Adv Genet 42: 273-286.
25. Nelson MR, Kardia SL, Ferrell RE, Sing CF (2001) A combinatorial partitioning method to identify multilocus; genotypic partitions that predict quantitative trait variation. Genome Res 11: 458-470.
26. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, et al. (2001) Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 69: 138-147.
27. Cordell HJ, Clayton DG (2002) A unified stepwise regression procedure for evaluating the relative effects of polymorphisms within a gene using case/control or family data: application to HLA in type 1 diabetes. Am J Hum Genet 70: 124-141.
28. Tahri-Daizadch N, Tregouet DA, Nicaud V, Manuel N, Cambien F, et al. (2003) Automated detection of informative combined effects in genetic association studies of complex traits. Genome Res 13: 1952-1960.
29. Slonim N, Atwal GS, Tkacik G, Bialek W (2005) Estimating mutual information and multi-information in large networks. arXiv:cs.IT/0502017.
30. Khan S, Bandyopadhyay S, Ganguly AR, Saigal S, Erickson DJ, et al. (2007) Relative performance of mutual information estimation methods for quantifying the dependence among short and noisy data. Phys. Rev. E 76, 026209.
31. Brenner N, Strong SP, Koberle R, Bialek W, de Ruyter van Steveninck RR (2000) Synergy in a neural code. Neural Cornput 12: 1531-1552.
32. Gat I, Tishby N (1999) Synergy and redundancy among brain cells of behaving monkeys. Neural Information Processing Systems.
33. Klein KO, Baron J, Colli MJ, McDonnell DP, Cutler GB Jr (1994) Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest 94: 2475-2480.
34. Paris F, Servant N, Terouanne B, Balaguer P, Nicolas JC, et al (2002) A new recombinant cell bioassay for ultrasensitive determination of serum estrogenic bioactivity in children. J Clin Endocrinol Metab 87: 791-797.
35. Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, et al. (2006) Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 118: 2281-2284.
36. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, et al. (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356: 1876-1881.
37. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, et al. (1999) Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91: 1475-1479.